Upgrade to SI Premium - Free Trial

BofA Securities stays Underperform on Sarepta Therapeutics (SRPT): data update 'directionally positive'

March 25, 2026 3:02 PM
BofA Securities analyst Tazeen Ahmad reiterated an Underperform rating and $19.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles